Ars Pharmaceuticals Inc (SPRY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ARS Pharmaceuticals, Inc. Is Being Looked Into For Violating Securities Laws And The Schall Law Firm Urges Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc's Possible Securities Fraud And Shareholders Are Invited To Contribute
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why
ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ARS Pharmaceuticals, Inc. May Have Violated Securities Regulations And The Schall Law Firm Seeks Investor Participation In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
ARS Pharmaceuticals' neffy, a needle-free nasal spray for Type I allergic reactions, received early FDA approval, driving a 120% YTD share price increase. Neffy addresses a significant unmet need, potentially capturing a large market share from injectable epinephrine products like EpiPen, with projected peak revenues of ~$750m annually. Despite initial FDA rejection, neffy's approval is backed by compelling clinical data, and ARS plans to expand into Europe, China, Japan, and Australia.
The Schall Law Firm Is Looking Into Whether ARS Pharmaceuticals Inc Committed Securities Law Violations And Stockholders Are Urged To Join The Investigation
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc. May Have Defrauded The Public And The Schall Law Firm Wants Impacted Investors To Reach Out About An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into Whether ARS Pharmaceuticals Inc Committed Securities Related Infractions And Shareholders Are Urged To Help
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc. May Have Violated Securities Laws And The Schall Law Firm Seeks Investor Participation In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged By The Schall Law Firm To Be A Part Of An Investigation Into ARS Pharmaceuticals Inc For Potential Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc. Might Have Committed Securities Law Violations And The Schall Law Firm Wants Investors To Partake In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc's Potential Securities Fraud And Affected Shareholders Are Encouraged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
